Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

Fecha de publicación: 01/11/2015

Autores de IIS La Fe

Miguel Ángel Sanz Alonso

Autor

Participantes ajenos a IIS La Fe

Sanford D
Lo-Coco F
Di Bona E
Coutre S
Altman JK
Wetzler M
Allen SL
Ravandi F
Kantarjian H
Cortes JE

Grupos

Hematología y Hemoterapia

Investigador Principal

Javier De La Rubia Comos

Abstract

Treatment of acute promyelocytic leukaemia (APL) with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is highly effective first-line therapy, although approximately 5-10% of patients relapse. Tamibarotene is a synthetic retinoid with activity in APL patients who relapse after chemotherapy and ATRA, but has not been studied in relapse after treatment with ATO and ATRA. We report on a phase II study of tamibarotene in adult patients with relapsed or refractory APL after treatment with ATRA and ATO (n=14). Participants were treated with tamibarotene (6mg/m(2)/d) during induction and for up to six cycles of consolidation. The overall response rate was 64% (n=9), the rate of complete cytogenetic response was 43% (n=6) and the rate of complete molecular response was 21% (n=3). Relapse was frequentwith 7 of 9 responders relapsing after a median of 46months (range 16-268months). The median event-free survival (EFS) was 35months [95% confidence interval (CI) 0-86months] and the median overall survival (OS) was 95months (95% CI 59-131months). These results demonstrate that tamibarotene has activity in relapsed APL after treatment with ATO and ATRA and further studies using tamibarotene as initial therapy and in combination with ATO are warranted.

Datos de la publicación

ISSN/ISSNe:: 0007-1048, 1365-2141
Tipo:: Article
Páginas:: 471-477
DOI:: 10.1111/bjh.13607
Factor de Impacto:: 2,297 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Sanford D:: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Lo-Coco F:: Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy
Sanz MA:: Hematology Department, Hospital Universitario La Fe, Valencia, Spain

Department of Medicine, University of Valencia, Valencia, Spain
Di Bona E:: Hematology Unit, San Bortolo Hospital, Vicenza, Italy
Coutre S:: Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA
Altman JK:: Robert H. Lurie Comprehensive Cancer Center, Northwestern University School of Medicine, Chicago, IL, USA
Wetzler M:: Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
Allen SL:: Department of Medicine, Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, NY, USA
Ravandi F:: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Kantarjian H:: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Cortes JE:: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Keywords

Acute promyelocytic leukaemia; tamibarotene; all-trans retinoic acid; arsenic trioxide; clinical trial

Campos de estudio

Proyectos asociados

RED DE INVESTIGACION COOPERATIVA DE CANCER

RD06/0020/0031 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006

PROYECTO CAIBER

CAI08/01/0061 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009

CREACION Y MEJORA DE INFRAESTRUCTURAS EN MEDICINA REGENERATIVA

Investigador Principal: FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA

PLE2009-0141 ACI-PLAN E . MINISTERIO DE CIENCIA E INNOVACION; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009